Journal: Materials Today Bio
Article Title: ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy
doi: 10.1016/j.mtbio.2026.102819
Figure Lengend Snippet: Preparation and characterization of the conjugates (A) Schematic diagram of responsive release of the conjugates. (B) Particle size and distribution of aVEGFA, MPEG-aVEGFA, and the conjugates. (C) Particle size changes of aVEGFA, MPEG-aVEGFA, and the conjugates after incubation in hydrogen peroxide. (D) Transmission electron microscopy images of aVEGFA and the conjugates, scale bar = 100 nm. (E–G) Schematic diagram and quantitative results of in vitro experiments assessing corneal penetration ability of FITC-aVEGFA. (H, I) Schematic diagram and quantitative results of in vitro experiments assessing corneal penetration ability of FITC-aPDL1. (J, K) Cytotoxicity evaluation of TAT-MPEG-aVEGFA on HCE-T cells and ARPE19 cells. (L, M) Scratch assay results estimating angiogenesis inhibition, and quantitative analysis. n.s. (not significant) p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control. Abbreviations: aVEGFA, anti–vascular endothelial growth factor A antibody; TAT-MPEG, trans-activator of transcription peptide–methoxy polyethylene glycol; ARPE-19, human retinal pigment epithelial cell line; HCE-T, human corneal epithelial cell line.
Article Snippet: Murine melanoma (B16) cells were obtained from COBIOER Biotechnology (Nanjing, China), human retinal pigment epithelial cell line (ARPE-19) cells and human corneal epithelial cell line (HCE-T) cells were obtained from ProCell Biotechnology (Wuhan, China), HUVECs were obtained from SUNNCELL Biotechnology (Wuhan, China).
Techniques: Incubation, Transmission Assay, Electron Microscopy, In Vitro, Wound Healing Assay, Inhibition, Control